Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

Journal of clinical pharmacology - 1 Jan 2007

Kim Kyoung-Ah, Park Pil-Whan, Lee Ock-Je, Kang Dong-Kyun, Park Ji-Young

Abstract excerpt

Simvastatin, a cholesterol-lowering agent, is mainly metabolized by CYP3A4/5. The objective of this study was to investigate the effect of CYP3A5*3 genotype on the pharmacokinetics of simvastatin in humans. Twenty-two men with CYP3A5*1/*1 (n = 4), CYP3A5*1/*3 (n = 8), or CYP3A5*3/*3 (n = 10) genotypes were enrolled. Each subject ingested a 20-mg dose of simvastatin, and plasma simvastatin concentrations were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Analysis of Variance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Half-Life

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Simvastatin

Source

Identifiers

PMID: 17192506
DOI: 10.1177/0091270006295063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.PMID 17192506Read ↗

Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.Semantic proximity Read ↗

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.Semantic proximity Read ↗

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.Semantic proximity Read ↗

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.Semantic proximity Read ↗

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.Semantic proximity Read ↗

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean SubjectsSemantic proximity Read ↗

Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.Semantic proximity Read ↗

CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin.Semantic proximity Read ↗

The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.Semantic proximity Read ↗

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.